OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

Market Cap	107.74B
Revenue (ttm)	78.80B
Net Income (ttm)	9.51B
Shares Out	16.15M
EPS (ttm)	623.09
PE Ratio	10.70
Forward PE	n/a
Dividend	100.00 (1.49%)
Ex-Dividend Date	n/a

Volume	49,954
Average Volume	472,847
Open	6,650.00
Previous Close	6,700.00
Day's Range	6,640.00 - 6,740.00
52-Week Range	4,855.00 - 10,430.00
Beta	0.55
RSI	53.18
Earnings Date	Mar 12, 2025

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 131030

Financial Performance

In 2023, OPTUS Pharmaceutical's revenue was 72.43 billion, an increase of 23.47% compared to the previous year's 58.66 billion. Earnings were 10.76 billion, an increase of 114.69%.